James Crowe, MD, and members of his lab at Vanderbilt University Medical Center who have pioneered rapid development of monoclonal antibody treatments for life-threatening viral diseases including COVID-19, were featured Sunday on a CBS News 60 Minutes segment titled “The Last Pandemic.”

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.

Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.